Nephrology
Conference Coverage
Finerenone’s heart benefits hold up in T2D patients without CVD
In the FIDELIO-DKD trial, cardiovascular benefits from a nonsteroidal mineralocorticoid antagonist held, regardless of CVD history, in T2D...
News
New guidelines address diabetes management in kidney disease
The Kidney Disease: Improving Global Outcomes synopsis document is aimed at primary care physicians and nonnephrology specialists, as well as...
Conference Coverage
Novel drug slows progression of diabetic kidney disease
Finerenone, a selective, nonsteroidal mineralocorticoid receptor antagonist, significantly reduced both renal and cardiovascular events, with good...
Original Research
Retrospective Review on the Safety and Efficacy of Direct Oral Anticoagulants Compared With Warfarin in Patients With Cirrhosis
A retrospective chart review of adult patients with cirrhosis taking either DOACs or warfarin found no statistically significant differences in...
Conference Coverage
Dapagliflozin’s CKD performance sends heart failure messages
The recently reported DAPA-CKD trial results focused on patients with renal disease, but the findings also resonate for heart failure clinicians...
News
Deaths sky high in hospitalized COVID patients with kidney injury
“We may be facing an epidemic of post–COVID-19 kidney disease and that, in turn, could mean much greater numbers of patients who require kidney...
News
Real-world data show SGLT2 inhibitors for diabetes triple DKA risk
The findings are based on the use of three different SGLT2 inhibitors in Canada and the United Kingdom.
News
Where does dexamethasone fit in with diabetic ketoacidosis in COVID-19?
Author of new article discussing considerations around diabetic ketoacidosis in the setting of COVID-19 also speaks to the findings this week that...
Conference Coverage
RA magnifies fragility fracture risk in ESRD
MAUI, HAWAII – “Fracture prevention prior to initiation of dialysis should be a focus of care in patients with RA.” – Dr. Renée Peterkin-McCalman...
Article
FDA approves cefiderocol for multidrug-resistant, complicated urinary tract infections
The approval is for patients with limited or no alternative treatment options and includes a warning of Fetroja’s higher all-cause mortality rate...